Sage faces third study fail in six months as Alzheimer's can­di­date miss­es Phase 2 goal

Sage Ther­a­peu­tics is reel­ing from an­oth­er mid-stage set­back as its in­ves­ti­ga­tion­al med­i­cine dalzanem­dor has missed the mark in a Phase 2 mild cog­ni­tive im­pair­ment tri­al …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER